ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43


Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases

TORONTO and CAMBRIDGE, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated antibody candidates targeting the neurotoxic form of TAR DNA-binding protein 43 (TDP-43), a protein found in all cells and implicated as a root cause in a spectrum of diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

New data generated by ProMIS’ unique drug discovery and development platform demonstrate that several antibody candidates show selectivity for toxic, misfolded intracellular aggregates of TDP-43 with no binding to normal TDP-43 located in the cell nucleus. ProMIS antibody candidates also show selective binding to the pathogenic, misfolded form of TDP-43 in post-mortem brain tissue from patients with FTD.

“The momentum behind each of our programs is palpable,” said Elliot Goldstein, MD, ProMIS Neurosciences President and CEO. “In the past 30 days, we’ve announced data advancing our development programs selectively targeting toxic misfolded proteins for treatment of Alzheimer’s and Parkinson’s disease and Multiple System Atrophy (MSA), ALS and FTD. Yesterday, Biogen’s decision to submit its amyloid-beta targeting drug candidate, aducanumab,  for FDA approval signaled a milestone shift in the promise of next-generation amyloid-beta targeting drugs. Our lead program, PMN310, offers sniper-like precision for the toxic, misfolded form of amyloid beta, a key feature that offers important potential advantages compared to aducanumab. We will continue to support the patient community by advancing our programs, in particular PMN310 for Alzheimer’s disease, leveraging our proprietary, drug discovery platform.”

To learn more about the search for therapies for Alzheimer’s, Parkinson’s and other neurodegenerative diseases, listen to the podcast, Saving Minds, at iTunes or Spotify.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at, follow us on Twitter and LinkedIn

For media inquiries, please contact:
Shanti Skiffington
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Huhtamäki Oyj issues a EUR 175 million bond13.11.2019 16:30:00 CETPress release

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 13.11.2019 AT 17:30 Huhtamäki Oyj issues a EUR 175 million bond NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Huhtamäki Oyj issues a senior unsecured bond of EUR 175 million. The seven-year bond will mature on November 20, 2026 and carry a fixed interest at the rate of 1.125 percent per annum. The bond was allocated to approximately 40 investors. Huhtamäki Oyj will submit an application for the admission to trading of the bond on the official list of Nasdaq Helsinki Ltd. The proceeds from the bond offering will be used for refinancing and general corporate purposes. OP Corporate Bank plc and Skandinaviska Enskilda Banken AB (publ) act as joint lead managers for the issue of the bond. For further information,

Metso’s Nomination Board proposes Jukka Moisio to be elected Chair of the Board of Directors of the future Neles Corporation13.11.2019 16:15:00 CETPress release

Metso’s Nomination Board proposes Jukka Moisio to be elected Chair of the Board of Directors of the future Neles Corporation Metso Corporation, Stock exchange release, November 13, 2019, at 5:15 p.m. EET The Shareholders’ Nomination Board of Metso Corporation proposes the election of Jukka Moisio (b.1961, M.Sc. Econ., MBA) as Chair of the Board of Directors of the future Neles Corporation. Jukka Moisio has previously served as CEO of Huhtamäki Oyj (from 2008 to 2019) and Ahlstrom Oyj (from 2004 to 2008), in addition to many other management positions at Ahlstrom Oyj (from 1991 to 2004). Metso’s Nomination Board will submit its proposal regarding Moisio’s election to Metso’s Board of Directors, which will make the final proposal, after being briefed by the Nomination Board, to Metso’s Annual General Meeting of shareholders to be held in March 2020. The Nomination Board will publish its proposal on the complete composition of the Neles Board in January 2020. According to the Nomination B

Unikt butikskoncept i Arvidsjaur när Elon Ljud&Bild, Elon och Em home går samman13.11.2019 16:15:00 CETPressemelding

Genom att kombinera vitvaror, hemelektronik och möbler i en och samma butik, skapas nu ett unikt butikskoncept i Arvidsjaur. Elon Ljud&Bild, Elon och Em home förenas i en och samma butik, något som är unikt för Sverige och ett led i en satsning på nytänkande utifrån kundens behov. Den nya butiken öppnar under v. 46. ”Hösten 2018 köpte vi Em home och hade redan då en vision om att kunna kombinera erbjudanden i våra kedjor. Vi har sedan tidigare i år ett nära samarbete med Elon och därför är det glädjande att se att detta nya koncept nu sjösätts. Det är unikt på marknaden och kunden har möbler, vitvaror och hemelektronik på ett ställe.” säger Anneli Sjöstedt, VD på Electra. Electra, som äger Elon Ljud&Bild (tidigare AudioVideo) och Em home, inledde tidigare i år ett nära varumärkessamarbete med Elon. I samarbetet läggs även fokus på inköp och logistik som skapar nya möjligheter till integration, som butikerna i Arvidsjaur nu gör. ”Genom samarbetet med Electra kommer vi att skapa Nordens

Skyharbour Option Partner Orano Canada Announces Upcoming Exploration Program at Preston Uranium Property13.11.2019 14:00:00 CETPress release

VANCOUVER, British Columbia, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce the Company’s option partner Orano Canada Inc. (“Orano Canada”) has announced details for their upcoming 2020 exploration program at the Preston Uranium Project located in the western Athabasca Basin near NexGen Energy Ltd.’s high-grade Arrow deposit and Fission Uranium Corp.’s Triple R deposit. Preston Uranium Project Claims Map: Skyharbour and Dixie Gold Inc. entered into an Option Agreement (the “Agreement”) with Orano Canada (previously AREVA Resources Canada Inc.) whereby Orano Canada has an option to acquire up to a 70% working interest in the Preston Uranium Project (see news release dated March 9th, 2017). Under the Agreement, Orano Canada will contribute cash and exploration program considerations totaling up to CA

Mandalay Resources Corporation tillkännager verkställande av slutgiltigt avtal för försäljning av silver-guldprojektet Challacollo i Chile13.11.2019 13:58:00 CETPressemelding

TORONTO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) är glada att meddela att ett slutgiltigt avtal med Aftermath Silver Ltd. (”Aftermath”) (TSX-V:AAG.H) ingåtts avseende den tidigare tillkännagivna transaktionen i vilken Aftermath kommer att förvärva Minera Mandalay Challacollo Limitada (”MMC”), som för närvarande äger silver-guldprojektet Challacollo i region I (Tarapaca) i Chile (”Challacollo-projektet”). I enlighet med transaktionsvillkoren kommer Aftermath att köpa 100 % av MMC i utbyte mot en total betalning på upp till 10 000 000 CAD, bestående av 7 000 000 CAD i icke villkorad betalning (”icke villkorad betalning”) plus en royalty i form av NSR (Net Smelter Return) om 3 % på produktionen vid Challacollo-projektet, på högst 3 000 000 CAD. Den icke villkorade betalningen ska betalas enligt följande: 1 000 000 CAD i kontanter ska betalas senast den 19 november 2019; 1 000 000 CAD i kontanter ska betalas sen